Teva issues €1B and $1.2B in senior notes to refinance debt, upsizes tender offer to $2.25B

TEVA PHARMACEUTICAL INDUSTRIES LTD

€1B of 4.125% Senior Notes due 2031; $500M of 6.000% notes due 2032; $700M of 5.750% notes due 2030.
Net proceeds fund tender offer for up to $2.25B (upsized from $2B) and repay other outstanding debt.
Notes are senior unsecured obligations guaranteed by Teva; customary covenants and events of default.
Issuance made under Teva's existing shelf registration statement filed February 2025.

item 1.01item 2.03item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.